hUCB

Phase 2Biologic

SStemCyte Taiwan Co., Ltd.

hUCB is one of 63 biologic programs targeting Cerebral Palsy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

Ischemic StrokeActive, not recruiting

Cerebral PalsyPhase 1

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

2 2

Repatha

Amgen

Preclinical

2 3

Levaquin

WWim Janssens

Preclinical

3 4

hUCB

SStemCyte Taiwan Co., Ltd.

Phase 2

1 5

Tylenol

KKenvue Brands

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Drug Therapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Ischemic Stroke

NCT06040476

Q4 2028

Phase 1Not yet recruiting

Cerebral Palsy

NCT06377982

Clinical

Trials by Indication[1]

Cerebral Palsy1 trial

Human Umbilical Cord Blood Infusion in Patients with Cerebral Palsy

Not yet recruiting·SStemCyte Taiwan Co., Ltd.·Phase 1·NCT06377982·12 enrolled

Ischemic stroke1 trial

Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)

Not yet recruiting·SStemCyte, Inc.·Phase 2·NCT06040476·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for hUCB. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hUCB compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hUCB. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — StemCyte Taiwan Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SStemCyte Taiwan Co., Ltd.

hUCB

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Cerebral Palsy1 trial

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News